CA209-650
17 Mar 2017
Trial Summary
A phase 2 trial of nivolumab plus ipilimumab, ipilimumab alone, or cabazitaxel in men with metastatic castration-resistant prostate cancer
Acronym:
Checkmate 650
ACTRN/NCT /ethics:
NCT02985957
Scientific title:
Study of Nivolumab Plus Ipilimumab, Ipilimumab or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer
Sponsor / Cooperative group:
Bristal-Myers Squibb
Trial & Patient Characteristics
| Cancer Type | Prostate |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II |
| Age Range | 18+ years |
| Sex | Male |
| Tumour Stream | Prostate cancer |
| Cancer Stage | Metastatic or Widespread |
| Anticipated Start Date | 2017-03-17 |
| Anticipated End Date | 2022-05-30 |
Participating Hospitals
| Hospital | Lyell McEwin Hospital |
|---|---|
| Clinical Trial Coordinator | Andy Phay |
| andy.phay@sa.gov.au | |
| Phone | 08 8282 0833 |
| Principal Investigator | Dr Christopher Hocking |
| Recruitment Status | Recruiting |